Population pharmacokinetic modeling of GS‐441524, the active metabolite of remdesivir, in Japanese COVID‐19 patients with renal dysfunction

Remdesivir, a prodrug of the nucleoside analog GS‐441524, plays a key role in the treatment of coronavirus disease 2019 (COVID‐19). However, owing to limited information on clinical trials and inexperienced clinical use, there is a lack of pharmacokinetic (PK) data in patients with COVID‐19 with spe...

Descripción completa

Detalles Bibliográficos
Autores principales: Sukeishi, Asami, Itohara, Kotaro, Yonezawa, Atsushi, Sato, Yuki, Matsumura, Katsuyuki, Katada, Yoshiki, Nakagawa, Takayuki, Hamada, Satoshi, Tanabe, Naoya, Imoto, Eishi, Kai, Shinichi, Hirai, Toyohiro, Yanagita, Motoko, Ohtsuru, Shigeru, Terada, Tomohiro, Ito, Isao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8646568/
https://www.ncbi.nlm.nih.gov/pubmed/34793625
http://dx.doi.org/10.1002/psp4.12736

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8646568/
https://www.ncbi.nlm.nih.gov/pubmed/34793625
http://dx.doi.org/10.1002/psp4.12736

Ejemplares similares